Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -24,204 | -26,767 | -20,837 | -23,792 | -25,244 |
| Depreciation Amortization | 73 | 272 | 184 | 169 | 176 |
| Accounts receivable | 32 | 31 | 50 | -111 | -48 |
| Other Working Capital | -525 | -680 | -404 | 4,421 | 61 |
| Other Operating Activity | 7,551 | 8,854 | 2,354 | -1,626 | 6,264 |
| Operating Cash Flow | $-17,073 | $-18,289 | $-18,654 | $-20,938 | $-18,791 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -18 | -16 | -48 | -58 | -10 |
| Investing Cash Flow | $-18 | $-16 | $-48 | $-58 | $-10 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 11,503 | 15,715 | N/A | N/A | 78,777 |
| Other Financing Activity | -381 | -1,965 | -41 | -42 | -4,223 |
| Financing Cash Flow | $11,122 | $13,750 | $-41 | $-42 | $74,554 |
| Exchange Rate Effect | -590 | 1,379 | 565 | 2,246 | N/A |
| Beginning Cash Position | 21,886 | 25,493 | 44,055 | 64,535 | 11,191 |
| End Cash Position | 15,328 | 22,317 | 25,878 | 45,744 | 66,943 |
| Net Cash Flow | $-6,558 | $-3,176 | $-18,178 | $-18,791 | $55,752 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,073 | -18,289 | -18,654 | -20,938 | -18,791 |
| Capital Expenditure | -18 | -16 | -48 | -58 | -10 |
| Free Cash Flow | -17,090 | -18,305 | -18,701 | -20,995 | -18,802 |